目的探讨卡比多巴/肠内混悬药物左旋多巴(Duopa)治疗帕金森病晚期患者的运动障碍及异动症的效果。方法选取2015年2月至2016年2月中国医科大学附属盛京医院收治的126例帕金森病晚期患者,将其随机分为对照组(n=64)及观察组(n=62),对照组在对照组基础上采取多巴丝肼治疗,观察组采取Duopa治疗,两组患者的治疗周期均为12周,以统一帕金森评定量表(UPDRS)评价两组患者的临床疗效,同时监测患者的血常规、肝肾功能,观察患者的不良反应,比较两组药物治疗的安全性。结果治疗前,两组患者的UPDRSⅡ~Ⅳ各量表评分比较差异无统计学意义(P均>0.05);治疗后,两组患者的UPDRSⅡ~Ⅳ各量表评分比较均明显低于治疗前,且观察组明显低于对照组(P<0.05,P<0.01)。观察组患者剂末现象(93.55%vs 43.75%)、剂量高峰多动症(92.00%vs 42.32%)、开-关现象(91.42%vs 47.22%)、晨僵(93.75%vs 51.52%)、异动症(93.33%vs46.67%)、运动障碍(91.67%vs 45.45%)的总有效率均明显高于对照组(P<0.01,P<0.05)。治疗期间,观察组出现便秘1例,恶心2例,总药物不良反应发生率为4.84%(3/62);对照组出现便秘2例,恶心1例,总药物不良反应发生率为4.69%(3/64);两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论 Duopa能有效缓解帕金森病晚期患者的运动障碍及异动症,临床疗效确切,不良反应少。 Objective To investigate the effect of carbidopa / enteral suspension drug levodopa on dyskinesia and dyskinesia in patients with advanced Parkinson’s disease. Methods A total of 126 patients with advanced Parkinson’s disease who were admitted to Shengjing Hospital of China Medical University from February 2015 to February 2016 were randomly divided into control group (n = 64) and observation group (n = 62) The patients in the observation group received Duopa’s hydrazide treatment. The treatment group was treated with Duopa for 12 weeks. The UPDRS was used to evaluate the clinical efficacy of the two groups of patients while monitoring The patient’s blood, liver and kidney function, adverse reactions observed in patients, compared the safety of two groups of drug treatment. Results Before treatment, there was no significant difference in UPDRS Ⅱ ~ Ⅳ scores between the two groups (all P> 0.05). After treatment, UPDRSⅡ ~ Ⅳ scores in both groups were significantly lower than those before treatment, And the observation group was significantly lower than the control group (P <0.05, P <0.01). (93.55% vs 43.75%), ADHD (92.00% vs 42.32%), ON-OFF (91.42% vs 47.22%), morning stiffness (93.75% vs 51.52% 93.33% vs46.67%). The total effective rate of dyskinesia (91.67% vs 45.45%) was significantly higher than that of the control group (P <0.01, P <0.05). During the treatment, constipation was observed in 1 case, nausea in 2 cases and total adverse drug reaction in 4.84% (3/62) in the observation group. In the control group, constipation was found in 2 cases and nausea in 1 case. The total adverse drug reaction rate was 4.69% 3/64). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Duopa can effectively relieve dyskinesia and dyskinesia in patients with advanced Parkinson’s disease. The clinical effect is exact and there are few adverse reactions.